💊Kyowa Hakko Kirin News、Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application 20171010
💊Notice Regarding Implementation of New Drug Discovery Program “JOINUS” Using Drug Repositioning Compound Libraries by Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi Sankyo
🔬Elucidation of genome mutation in iPS cells | RIKEN
🎗Basic agreement on marine LNG fuel supply with Mitsubishi Corporation, Gas 4 Sea, Statoil